Eden Prairie, Minn. - Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, has announced a significant achievement in the healthcare sector. The company has been awarded a group purchasing agreement for its innovative thrombectomy products with Premier, Inc. The agreement is set to take effect on June 1, 2024.’
Premier, Inc. is a well-established healthcare improvement organization and one of the largest group purchasing organizations (GPOs) in the United States. It boasts a vast network of hospitals and healthcare providers that collectively focus on improving healthcare quality while reducing costs. This new partnership marks a milestone in Surmodics’ ongoing mission to make groundbreaking medical technologies more accessible to healthcare providers and patients across the nation.
Expanding Access to Innovative Thrombectomy Solutions’
Under the new agreement, Premier members will have the option to take advantage of specially pre-negotiated pricing and terms for Surmodics’ acclaimed Pounce and Pounce Venous Thrombectomy Systems. These systems represent cutting-edge innovation in the field of thrombectomy, which is the surgical removal of a blood clot from a blood vessel. The Pounce systems were developed to offer physicians efficient and effective tools to navigate the complex vascular networks of patients and ultimately save lives.
According to medical experts, thrombectomy is pivotal in treating patients who suffer from complications such as deep vein thrombosis and other life-threatening blood clot conditions. The Pounce and Pounce Venous Thrombectomy Systems have been widely recognized for their ability to remove blood clots quickly and with minimal trauma to surrounding tissues, thereby improving patient outcomes and recovery times.
Commitment to Healthcare Excellence’
Gary Maharaj, President and CEO of Surmodics, emphasized the importance of this partnership in a recent statement: “We are thrilled to collaborate with Premier, Inc. a leader in healthcare improvement. This agreement exemplifies our commitment to expanding the access and adoption of our life-saving thrombectomy technologies. Premier’s extensive network and proven track record make them an ideal partner to help drive the widespread use of our innovative Pounce and Pounce Venous Thrombectomy Systems.”
Premier members are renowned for their dedication to healthcare excellence, and the inclusion of Surmodics’ thrombectomy products in their purchasing options stands to significantly enhance patient care protocols. This agreement underscores Surmodics’ strategic focus on collaborating with influential healthcare organizations to bring its state-of-the-art medical devices to more hospitals and clinics.
A Strategic Move’
The strategic importance of this agreement cannot be understated. Group purchasing agreements like the one with Premier play a vital role in modern healthcare. They streamline procurement processes, reduce costs, and ensure that healthcare providers can access advanced medical technologies without the administrative burden of individual negotiations. For Surmodics, this agreement opens the door to a broader market and positions the company for accelerated growth and impact in the thrombectomy solutions space.
By offering special pricing and terms pre-negotiated by Premier, Surmodics ensures that Premier members can seamlessly integrate these advanced thrombectomy tools into their treatment regimens, thereby enhancing the quality of care provided to their patients.
Looking Ahead’
As the agreement comes into effect on June 1, 2024, healthcare providers within the Premier network can look forward to adopting these advanced thrombectomy systems with greater ease and affordability. Surmodics’ collaborative effort with Premier signifies an alignment of values and goals centered around better patient outcomes and streamlined healthcare delivery.
For hospitals and medical professionals, the enhanced accessibility to Surmodics’ Pounce and Pounce Venous Thrombectomy Systems promises to be an invaluable asset in their arsenal against thrombotic conditions. With innovative solutions like these, the future of thrombectomy looks remarkably promising.
Conclusion’
The award of this group purchasing agreement between Surmodics and Premier, Inc. marks a significant milestone in the medical device industry. It heralds an era of improved accessibility to innovative thrombectomy products, which translates into better patient care and outcomes. As we move towards the effective date, the healthcare landscape stands to gain immensely from this strategic collaboration.
Comments